Chapter title |
mRNA-Based Vaccines and Mode of Action
|
---|---|
Published in |
Current topics in microbiology and immunology, February 2021
|
DOI | 10.1007/82_2020_230 |
Pubmed ID | |
Authors |
Gergen, Janina, Petsch, Benjamin, Janina Gergen, Benjamin Petsch |
Abstract |
In the past 20 years, the mRNA vaccine technology has evolved from the first proof of concept to the first licensed vaccine against emerging pandemics such as SARS-CoV-2. Two mRNA vaccines targeting SARS-CoV-2 have received emergency use authorization by US FDA, conditional marketing authorization by EMA, as well as multiple additional national regulatory authorities. The simple composition of an mRNA encoding the antigen formulated in a lipid nanoparticle enables a fast adaptation to new emerging pathogens. This can speed up vaccine development in pandemics from antigen and sequence selection to clinical trial to only a few months. mRNA vaccines are well tolerated and efficacious in animal models for multiple pathogens and will further contribute to the development of vaccines for other unaddressed diseases. Here, we give an overview of the mRNA vaccine design and factors for further optimization of this new promising technology and discuss current knowledge on the mode of action of mRNA vaccines interacting with the innate and adaptive immune system. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 20% |
United States | 1 | 20% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 73 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 12 | 16% |
Student > Master | 5 | 7% |
Researcher | 5 | 7% |
Student > Doctoral Student | 4 | 5% |
Student > Ph. D. Student | 4 | 5% |
Other | 7 | 10% |
Unknown | 36 | 49% |
Readers by discipline | Count | As % |
---|---|---|
Nursing and Health Professions | 7 | 10% |
Biochemistry, Genetics and Molecular Biology | 5 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Chemistry | 4 | 5% |
Agricultural and Biological Sciences | 4 | 5% |
Other | 8 | 11% |
Unknown | 41 | 56% |